Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Standard Biotools Inc.

NASDAQ: LAB · Life Sciences · 6 alerts · CIK 1162194

Share price
$0.6210Close, Nov 16
Market cap
$245M
Shares outstanding
394.79MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Standard Biotools Inc. filings on SEC EDGAR ↗

4:37 PM ET 8-K
M&A Deal

Standard Biotools M&A Deal with Treeline Biosciences, Inc.

Standard BioTools Inc. provided a status update regarding its pending acquisition of Treeline Biosciences, Inc., specifically addressing stockholder litigation and demand letters. To avoid potential business delays and moot disclosure claims, the company issued supplemental disclosures to its definitive proxy statement ahead of the special meeting of stockholders scheduled for November 19, 2026.

Counterparty
Treeline Biosciences, Inc.
5:36 PM ET Form 4
Insider Buying

Standard Biotools Director Thomas D. Carey Buys $46.9K of Stock

Thomas D. Carey, Director, bought 75,000 shares of Standard Biotools Inc. at $0.6253 a share, worth $46.9K in total on Nov 5, 2026. Shares held after the trade: 419,456 (+21.8%).

Value
$46.9K
Shares
75,000
Price
$0.6253
Role
Director
Holding change
+21.8%
Trade date
Nov 5, 2026
4:45 PM ET 10-Q
Financial Results

Standard Biotools Q3 2026 Results: Turns Profitable, Net Income $13.5M

Standard BioTools reported a net income of $113.8 million for the nine months ended September 30, 2026, primarily driven by a $202.3 million gain on the sale of a business recorded in discontinued operations. However, the company experienced a loss from continuing operations of $57.7 million during the same period, reflecting ongoing restructuring and integration expenses.

Key figure
Net income $13.5M
8:23 AM ET 8-K
Divestiture

Standard Biotools Divestiture to Archimed

Standard BioTools Inc. completed the sale of its Microfluidics business to healthcare investment firm ARCHIMED. The divested business will now operate as a standalone independent entity named Biomark Scientific, focusing on high-throughput genomic profiling and microfluidics technology.

Counterparty
ARCHIMED

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.